Журнал "Медицинский совет. Кардиология" №14, 2018

Е.В. Филиппов, ФГБОУ ВО «Рязанский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России
Статья посвящена диагностике и ведению пациентов с миокардитом, а также его роли в развитии хронической сердечной недостаточности (ХСН). Определено место специфической терапии и подходы к лечению ХСН у пациентов с данной патологией.
E.V. Filippov, Ryazan State Medical University of the Ministry of Health of Russia, Ryazan

Myocarditis as a cause of chronic heart failure

The article is devoted to the diagnosis and management of patients with myocarditis, and its role in the development of chronic heart failure (CHF). It also determined the role of specific therapy and approaches to the treatment of CHF in patients with this pathology.

Загрузить

Список литературы

1. Corsten, M.F., Schroen, B., Heymans, S. Inflammation in Viral Myocarditis: Friend or Foe? Trends Mol Med, 2012, 18: 426-437.
2. Chandra N, Bastiaenen R, Papadakis M, Sharma S. Sudden cardiac death in young athletes: Practical challenges and diagnostic dilemmas. J Am Coll Cardiol, 2013, 61: 1027-1032.
3. Blauwet LA, Cooper LT. Myocarditis. Prog Cardiovasc Dis, 2010, 52: 274-288.
4. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2013, 380: 2163-2170.
5. Cooper LT Jr. Myocarditis. N Engl J Med, 2009, 360: 1526-1532.
6. Towbin JA, Lowbin AM, Colan S, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA, 2006, 296: 1867-1871.
7. Клинические рекомендации, Миокардиты, год утверждения: 2016. Доступно по ссылке: http://cr.rosminzdrav.ru/#!/recomend/131, дата последнего обновления: 10/08/2018).
8. Kashimura T, Kodama M, Hotta Y, et al. Spatiotemporal changes of coxsackievirus and adenovirus receptor in rat hearts during postnatal development and in cultured cardiomyocytes of neonatal rat. Virchows Arch, 2004, 444: 283-292.
9. Bültmann BD, Sotlar K, Klingel K. Parvovirus B19. N Engl J Med, 2004, 350(19): 2006-7.
10. Braunwald’s heart disease : a textbook of cardiovascular medicine. Edited by DL Mann, DP Zipes, P Libby, RO Bonow, E Braunwald. 10th edition. 1943 р.
11. Кардиология: национальное руководство. Под ред. Е.В. Шляхто. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2015.
12. 2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol, 2012, 21: 245-269.
13. Sagar S, Liu PP, Cooper LT Jr. Myocarditis. Lancet, 2012, 379: 738-745.
14. Pinamonti B, Alberti E, Cigalotto A, Dreas L, Salvi A, Silvestri F, Camerini F. Echocardiographic findings in myocarditis. Am J Cardiol, 1988, 62(4): 285-291.
15. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, Baughman KL, Kasper EK. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med, 2000, 342(15): 1077-1084.
16. Felker GM, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Baughman KL, Hare JM. Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol, 2000, 36(1): 227-232.
17. Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J, 2009, 30(16): 1995-2002.
18. Meune C, Spaulding C, Mahé I, Lebon P, Bergmann JF. Risks versus benefits of NSAIDs including aspirin in myocarditis: a review of the evidence from animal studies. Drug Saf, 2003, 26(13): 975-981.
19. Клинические рекомендации, Хроническая сердечная недостаточность, год утверждения: 2016. Доступно по ссылке: http://cr.rosminzdrav.ru/#!/recomend/134, дата последнего обновления: 10/08/2018.
20. Godsel LM, Leon JS, Wang K, Fornek JL, Molteni A, Engman DM. Captopril prevents experimental autoimmune myocarditis. J Immunol, 2003, 171: 346-352.
21. Reyes MP, Khatib R, Khatib G, Ho KL, Smith F, Kloner RA. Prolonged captopril therapy in murine viral myocarditis. J Cardiovasc Pharmacol Ther, 1998, 3: 43-50.
22. Bahk TJ, Daniels MD, Leon JS, Wang K, Engman DM. Comparison of angiotensin converting enzyme inhibition and angiotensin II receptor blockade for the prevention of experimental autoimmune myocarditis. Int J Cardiol, 2008, 125: 85-93.
23. Greenbaum R, Zucchelli P, Caspi A et al. Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency. Br J Clin Pharmacol, 2000, 49(1): 23-31.
24. Erhardt L, MacLean A, Ilgenfritz J et al. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group. Eur Heart J, 1995, 16(12): 1892-1899.
25. Galatius-Jensen S., Wroblewski H., Emmeluth C. et al. Plasma endothelin in congestive heart failure: effect of the ACE inhibitor, fosinopril. Cardiovasc Res, 1996, 32(6): 1148-1154.
26. Brown EJ Jr, Chew PH, MacLean A et al. Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Fosinopril Heart Failure Study Group. Am J Cardiol, 1995, 75(8): 596-600.
27. Zannad F, Chati Z, Guest M, Plat F. Differential effects of fosinopril and enalapril in patients with mild to moderate chronic heart failure. Fosinopril in Heart Failure Study Investigators. Am Heart J, 1998, 136(4 Pt 1): 672-680.
28. Sharma S, Deitchman D, Eni JS et al. The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group. Am J Ther, 1999, 6(4): 181-189.
29. Shettigar U, Hare T, Gelperin K et al. Effects of fosinopril on exercise tolerance, symptoms, and clinical outcomes in patients with decompensated heart failure. Congest Heart Fail., 1999, 5(1): 27-34.
30. Huang ZB, Deng CY, Lin MH, Yuan GY, Wu W. Fosinopril improves the electrophysiological characteristics of left ventricular hypertrophic myocardium in spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol, 2014, 387(11): 1037-1044.
31. He BX, Yu GL, Liang XQ. Effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in hypertensive rats. Hunan Yi Ke Da Xue Xue Bao, 2001, 26(2): 118-120.
32. Kindermann I, Kindermann M, Kandolf R, et al. Predictors of outcome in patients with suspected myocarditis. Circulation, 2008, 118: 639-648.
33. Nishioka T, Suzuki M, Onishi K, Takakura N, Inada H, Yoshida T, Hiroe M, Imanaka-Yoshida K. Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation. J Cardiovasc Pharmacol, 2007, 49(5): 261-268.
34. Lu Fang, Andrew J. Murphy, Anthony M. Dart. A Clinical Perspective of Anti-Fibrotic Therapies for Cardiovascular Disease. Front Pharmacol, 2017, 8: 186-192.
35. Veeraveedu PT, Watanabe K, Ma M, Thandavarayan RA, Palaniyandi SS, Yamaguchi K, Suzuki K, Kodama M, Aizawa Y. Comparative effects of torasemide and furosemide in rats with heart failure. Biochem Pharmacol, 2008, 75(3): 649-59.
36. Imazio M, Cooper LT. Management of myopericarditis. Expert Rev Cardiovasc Ther, 2013, 11(2): 193-201.
37. D’Ambrosio A, Patti G, Manzoli A, Sinagra G, Di Lenarda A, Silvestri F, Di Sciascio G. The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart, 2001, 85(5): 499-504.
38. Kühl U, Schultheiss HP. Viral myocarditis. Swiss Med Wkly, 2014, Oct 2, 144: w14010.
39. Dominguez F, Kühl U, Pieske B, Garcia-Pavia P, Tschöpe C. Update on Myocarditis and Inflammatory Cardiomyopathy: Reemergence of Endomyocardial Biopsy. Rev Esp Cardiol (Engl Ed), 2016, 69(2): 178-87.